Interference of PD-1/PD-L1 interaction by the administration of blocking antibodies (nivolumab-αPD1 or avelumab-αPD-L1) could enhance the potency of immunotherapy targeting PD-L1-expressing pancreatic cancers (PaCs), and this strategy has reached phase II clinical trials.8 Here, PDCD1 is linked to familial pancreatic carcinoma.